Merck & Co., Inc.
Financials
Valuation Metrics
Merck & Co., Inc.'s Market Cap is $362.46B. At end of 2025 it was $262.09B. Ranked #33 of 3,121 in US market (top 1%), #16 of 1,658 on NYSE (top 1.0%), #4 of 266 in Pharmaceuticals, Biotechnology & Life Sciences (top 2%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $362.46B | US#33/3,121 Sec#4/266 |
| Revenue | $66.40B | US#89/3,121 Sec#3/266 |
| Net Income | $3.17B | US#228/3,121 Sec#14/266 |
| Total Assets | $129.80B | US#134/3,121 Sec#6/266 |
| Net Assets | $41.93B | US#103/3,121 Sec#6/266 |
| Employees | 73,000 | US#176/3,121 Sec#6/266 |
| Value | ||
| P/E | 114.23x | US#2,123/3,121 Sec#66/266 |
| P/B | 8.64x | US#2,571/3,121 Sec#188/266 |
| P/S | 5.46x | US#2,363/3,121 Sec#79/266 |
| EV/EBITDA | 29.58x | US#2,209/3,121 Sec#61/266 |
| FCF Yield | 4.43% | US#1,539/3,121 Sec#46/266 |
| Profitability | ||
| ROE | 7.57% | US#1,632/3,121 Sec#54/266 |
| ROA | 2.44% | US#1,541/3,121 Sec#59/266 |
| Op. Margin | 16.65% | US#1,114/3,121 Sec#46/266 |
| Revenue Growth | 4.24% | US#1,883/3,121 Sec#118/266 |
| Earnings Growth | -80.66% | US#1,837/3,121 Sec#51/266 |
| Financial Health | ||
| Debt Ratio | 209.42% | US#1,836/3,121 Sec#203/266 |
| Total Debt | $53.91B | US#83/3,121 Sec#5/266 |
| FCF | $16.06B | US#43/3,121 Sec#4/266 |
| Cash | $6.85B | US#152/3,121 Sec#8/266 |
| Current Ratio | 1.32x | US#1,866/3,121 Sec#248/266 |
| Net Debt/EBITDA | 3.40x | US#1,718/3,121 Sec#67/266 |
| Dividend | ||
| Div. Yield | 2.29% | US#859/3,121 Sec#15/266 |
| Div. Growth | 5.31% | US#793/3,121 Sec#8/266 |
| Performance | ||
| 1Y Return | 81.54% | US#285/3,121 Sec#75/266 |
| 1M Return | -3.58% | US#280/3,121 Sec#33/266 |
| From 52W High | -6.48% | US#413/3,121 Sec#30/266 |
| 1Y MDD | -11.90% | US#132/3,121 Sec#4/266 |
| Trading | ||
| Volume | 6,502,304 shares | US#290/3,121 Sec#22/266 |
| Trading Value | $954M | US#109/3,121 Sec#5/266 |
| Per Share | ||
| EPS | $1.28 | US#1,591/3,121 Sec#43/266 |
| BPS | $16.98 | US#1,418/3,121 Sec#43/266 |
Company Info
Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. The company also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto TriUNO, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Numelvi, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Safeguard, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands. It has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates; AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types; licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova; and collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.